Diabetes mellitus after liver transplantation: pathogenesis, risk factors, verification, impact on prognosis

Cover Page

Cite item

Full Text

Abstract

Post-transplant diabetes mellitus (PTDM) is associated with increased morbidity and mortality after liver transplantation. The review presents literature data on current views on the pathogenesis, risk factors and verification of DM in the early and late posttransplant period. Particular attention is paid to the mechanisms of the diabetogenic action of cytostatics and immunosuppressants. The understanding of the mechanisms of occurrence, management of risk factors and early diagnosis of PTDM will contribute to prevention and the timely beginning of treatment.

About the authors

E. D Kosmacheva

Prof. S.V.Ochapovsky Clinical Hospital №1 of the Ministry of Health of the Krasnodar Region; Kuban State Medical University of the Ministry of Health of the Russian Federation

Email: anna-babich1@yandex.ru
д-р мед. наук, доц., зав. каф. терапии №1 ФПК и ППС, зам. глав. врача по медицинской части 350029, Russian Federation, Krasnodar, ul. 1 Maia, d. 16

A. E Babich

Prof. S.V.Ochapovsky Clinical Hospital №1 of the Ministry of Health of the Krasnodar Region; Kuban State Medical University of the Ministry of Health of the Russian Federation

Email: anna-babich1@yandex.ru
аспирант каф. терапии №1 ФПК и ППС, врач-гастроэнтеролог 350029, Russian Federation, Krasnodar, ul. 1 Maia, d. 16

References

  1. Davidson J, Wilkinson A, Dantal J. et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003; 75 (Suppl. 10): SS3-24. doi: 10.1097/01.TP.0000069952.49242.3E
  2. Stockmann M, Steinmuller T.H, Nolting S, Neuhaus P. Posttransplant diabetes mellitus after orthotopic liver transplantation. Trans Proceed 2002; 34 (5): 1571-2.
  3. Wilkinson A, Davidson J, Dotta F. et al. Guidelines for the treatment and management of new-onset diabetes after transplantation1. Clin Transpl 2005; 19 (3): 291-8. doi: 10.1111/j.1399-0012.2005.00359.x
  4. Sharif A, Hecking M, de Vries A.P.J. et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transpl 2014; 14 (9): 1992-2000. doi: 10.1111/ajt.12850
  5. Baid S, Cosimi A.B, Farrell M.L. et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72 (6): 1066-72.
  6. Lucey M.R, Terrault N, Ojo L. et al. Long-Term Management of the Successful Adult Liver Transplant: 2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3-26.
  7. Ruiz-Rebollo M.L, Sánchez-Antolín G, García-Pajares F. et al. Risk of development of the metabolic syndrome after orthotopic liver transplantation. Transplant Proc 2010; 42 (2): 663-5.
  8. Pageaux G.P, Faure S, Bouyabrine H. et al. Long-term outcomes of liver transplantation: diabetes mellitus. Liver Transpl 2009; 15 (Suppl. 2): 79-82.
  9. Laura De Luca, Rachel Westbrook, Emmanuel A. Tsochatzis Royal Metabolic and cardiovascular complications in the liver transplant recipient. Ann Gastroenterol 2015; 28 (2): 182-92.
  10. Laish I., Braun M, Mor E. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011.
  11. Laryea M., Watt K.D, Molinari M.et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13 (8): 1109-14.
  12. Bianchi G., Marchesini G, Marzocchi R. et al. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14 (11): 1648-54.
  13. Cole E.H, Johnston O, Rose C.L, Gill J.S. Impact of acute rejection and new-onset diabetes on longterm transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3: 814-21.
  14. Watt K.D., Pedersen R.A, Kremers W.K. et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10 (6): 1420-7.
  15. John P.R, Thuluvath P.J. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 2001; 34 (5): 889-95.
  16. Kato T. Glucose intolerance, as пeflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiology 2004; 43 (6): 1034
  17. Veldt B.J., Poterucha J.J, Watt K.D. et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9 (6); 1406-13.
  18. Hanouneh I.A, Feldstein A.E., McCullough A.J. et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14 (9): 1287-93.
  19. Moon J.I., Barbeito R, Faradji R.N. et al. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation 2006; 82 (12): 1625-8.
  20. Скляник И.А., Шамхалова М.Ш., Шестакова М.В. Посттрансплантационный сахарный диабет. Обзор литературы. Сахарный диабет. 2015; 18 (2): 20-31.
  21. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. Вып. 8. М.: УП ПРИНТ, 2017.
  22. Общероссийская общественная организация трансплантологов «Российское трансплантологическое общество». Трансплантация сердца. Национальные клинические рекомендации, 2013 год.
  23. Bayer N., Philip T., Cochetti P.et al. Association of metabolic syndrome with development of new onset diabetes after transplantation. Transplantation 2010; 90: 861-6.
  24. Porrini E., Silva I., Ibernon M. et al. The natural history of prediabetes and new onset diabetes after transplantation. Proceedings of the ERA-EDTA 50th Congress; 2013; May 18-21; Istanbul, Turkey. p. Abstract T002.
  25. Kuo H.T, Sampaio M.S, Ye X. et al. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010; 89 (9): 1134-40.
  26. Porrini E., Delgado P, Alvarez A. et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant 2007; 23: 1436-41.
  27. Hornum M., Jørgensen K.A, Hansen JM et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin J Am Soc Nephrol 2010; 5: 709-16.
  28. Vincenti F., Friman S., Scheuermann E. et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-14.
  29. Wissing K., Kuypers, D., Abramowicz, D. et al. Conversion from tacrolimus to cyclosporin A improves glucose metabolism in patients with new-onset diabetes after transplantation: Interim analysis of a prospective and randomized study. Presented at the 16th ESOT Congress; September 8-11, 2013; Vienna, Austria. p. Abstract 231475.
  30. Pham P.C.T, Pham P.M.T, Pham S.V. et al. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2 (2): 366-73. doi: 10.2215/cjn.02960906
  31. Van Laecke S, Van Biesen W., Verbeke F. et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009; 9 (9): 2140-9. doi: 10.1111/j.1600-6143.2009.02752.x
  32. Augusto J.F., Subra J.F., Duveau A. et al. Relation between pretransplant magnesemia and the risk of new onset diabetes after transplantation within the first year of kidney transplantation. Transplantation 2014; 97 (11): 1155-60.
  33. Bloom R.D., Lake J.R. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6 (10): 2232-7.
  34. Bigam D.L., Pennington J.J, Carpentier A.et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32: 87-90.
  35. Trail K.C, McCashland T.M, Larsen J.L. et al. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 1996; 2: 276-83.
  36. Tueche S.G. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 2003; 35: 1466-8.
  37. Chan J.C, Cockram C.S, Critchley J.A. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996; 15: 135-57.
  38. Yates C.J, Cohney S.J. Prediction and diagnosis of post transplant diabetes. Curr Diabetes Rev 2015; 11 (3): 170-4.
  39. Valderhaug T.G, Hjelmesaeth J, Hartmann A.et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011; 54: 1341-9.
  40. Sharif A, Moore R.H, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. Transplantation 2006; 82: 1667-72.
  41. Lane J.T, Dagogo-Jack S. Approach to the patient with new-onset diabetes after transplant (NODAT). J Clin Endocrinol Metab 2011; 96 (11): 3289-97.
  42. Valderhaug T.G, Jenssen T., Hartmann A. et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009; 88: 429-34.
  43. Armstrong K.A, Prins J.B, Beller E.M et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol 2006; 1: 100-8.
  44. Hecking M, Werzowa J, Haidinger M. et al. New-onset diabetes after transplantation: Development, prevention, treatment. Nephrol Dial Transplant 2013; 28: 550-66. PubMed: 23328712.
  45. Hecking M, Kainz A, Werzowa J et al. Glucose metabolism after renal transplantation. Diabetes Care 2013; 36: 2763-71. PubMed: 23656979.
  46. Caillard S, Eprinchard L, Perrin P et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: Role of systematics screening by oral glucose tolerance test. Transplantation 2011; 91: 757-64.
  47. Valderhaug T.G, Hjelmesaeth J., Jenssen T. et al. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall longterm graft losses. Transplantation 2012; 94: 714-20.
  48. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36 (Suppl. 1): S11-S66.
  49. Sharif A., Baboolal K. Diagnostic application of the A assay in renal disease. J Am Soc Nephrol 2010; 21: 383-5. PubMed: 20133482.
  50. Shabir S., Jham S, Harper L. et al. Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation. Transplant Int 2013; 26: 315-21.
  51. Werzowa J, Hecking M, Haidinger M. et al. Curr Diab Rep 2015; 15: 27. doi: 10.1007/s11892-015-0601-x
  52. Perito E.R., Lustig R.H, Rosenthal P. Prediabetes in Pediatric Recipients of Liver Transplant: Mechanism and Risk Factors. J Pediatr 2017; 182: 223-31. e3. doi: 10.1016/j.jpeds.2016.11.070. Epub 2016 Dec 29.
  53. Bergrem H.A, Valderhaug T.G, Hartmann A. et al. Undiagnosed diabetes in kidney transplant candidates: A case-finding strategy. Clin J Am Soc Nephrol 2010; 5: 616-22. PubMed: 20133490.
  54. Tietge U.J., Selberg O, Kreter A et al. Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation. Liver Transpl 2004; 10 (8): 1030-40.
  55. Бондарь И.А., Климонтов В.В., Мигуськина Е.И. и др. Трансплантация печени по поводу первичного билиарного цирроза у больного сахарным диабетом. Cахарный диабет. 2011; 3: 113-5.
  56. Sharif A., Baboolal K. Risk factors for new onset diabetes after transplantation. Nat Rev Nephrol 2010; 6: 415-23.
  57. Hampton T.. Diabetes drugs tied to fractures in women. JAMA 2007; 297: 1645-7.
  58. Pham P.T., Pham P.C., Lipshutz G.E. et al. New Onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin N Am 2007; 36: 873-90.
  59. Valantine H., Rickenbaker P., Kemna M. et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease. Circulation 2001; 103: 2144-52.
  60. Bodziak K.A, Hricik D.E. New-onset diabetes mellitus after solid organ transplantation. Transplant Int2009; 22: 519-30.
  61. Hjelmesaeth J., Hartmann A., Leivestad T. et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-95.
  62. Готье С.В., Хомяков С.М., Арзуманов С.В. Трансплантация печени. Национальные клинические рекомендации. (Утверждены решением Координационного Совета общероссийской общественной организации трансплантологов «Российское трансплантологическое общество».) М., 2013. http://transpl.ru/images/cms/ /data/pdf/nacional_nye_klinicheskie_rekomendacii_po_transplantacii_pecheni.pdf nacional_nye_klinicheskie_rekomendacii_po_transplantacii_pecheni.pdf [in Russian]
  63. Готье С.В., Мойсюк Я.Г. Трансплантология. Фармакотерапия без ошибок. М., 2014.
  64. Государственный реестр лекарственных средств: grls.rosminzdrav.ru.
  65. Johnston O, Rose C.L, Webster A.C, Gill J.S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-8.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies